Compare WLKP & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WLKP | TECX |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 743.7M | 618.9M |
| IPO Year | 2014 | 2018 |
| Metric | WLKP | TECX |
|---|---|---|
| Price | $21.03 | $20.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $71.00 |
| AVG Volume (30 Days) | 17.1K | ★ 223.0K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 9.00% | N/A |
| EPS Growth | N/A | ★ 40.70 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,166,695,000.00 | N/A |
| Revenue This Year | $16.25 | N/A |
| Revenue Next Year | $5.23 | N/A |
| P/E Ratio | $15.30 | ★ N/A |
| Revenue Growth | ★ 2.71 | N/A |
| 52 Week Low | $17.75 | $15.60 |
| 52 Week High | $23.88 | $39.53 |
| Indicator | WLKP | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 48.02 | 29.83 |
| Support Level | $21.10 | $17.27 |
| Resistance Level | $22.27 | $23.61 |
| Average True Range (ATR) | 0.30 | 1.20 |
| MACD | 0.00 | 0.17 |
| Stochastic Oscillator | 47.14 | 7.40 |
Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develops ethylene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products, such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen, to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.